CLINICAL TRIALS PROFILE FOR FLUVOXAMINE MALEATE

All Clinical Trials for FLUVOXAMINE MALEATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00352768 ↗	Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents	Terminated	Solvay Pharmaceuticals	Phase 4	2006-08-01	This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder
NCT00353028 ↗	Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents	Completed	Solvay Pharmaceuticals	Phase 4	2006-10-01	This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state
NCT01933919 ↗	A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder	Completed	Meiji Seika Pharma Co., Ltd.	Phase 3	2013-08-14	The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD). The objective of the second phase of the study is to evaluate the long-term safety and efficacy of fluvoxamine in pediatric/adolescent patients with OCD.
NCT01933919 ↗	A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder	Completed	AbbVie	Phase 3	2013-08-14	The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD). The objective of the second phase of the study is to evaluate the long-term safety and efficacy of fluvoxamine in pediatric/adolescent patients with OCD.
NCT02194075 ↗	Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder	Completed	Guangdong General Hospital	Phase 4	2013-10-01	Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.
NCT02194075 ↗	Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder	Completed	Guangdong Provincial People's Hospital	Phase 4	2013-10-01	Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Alphacait, LLC	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.

Clinical Trial Conditions for FLUVOXAMINE MALEATE

Condition Name

Condition Name for FLUVOXAMINE MALEATE
Intervention	Trials
Obsessive Compulsive Disorder	3
Social Anxiety Disorder	1
Major Depressive Disorder	1
Metastatic Cancer	1

Condition MeSH

Condition MeSH for FLUVOXAMINE MALEATE
Intervention	Trials
Compulsive Behavior	3
Obsessive-Compulsive Disorder	3
Disease	3
Compulsive Personality Disorder	3

Clinical Trial Locations for FLUVOXAMINE MALEATE

Trials by Country

Trials by Country for FLUVOXAMINE MALEATE
Location	Trials
Japan	3
China	2
United States	1

Trials by US State

Trials by US State for FLUVOXAMINE MALEATE
Location	Trials
New York	1

Clinical Trial Progress for FLUVOXAMINE MALEATE

Clinical Trial Phase

Clinical Trial Phase for FLUVOXAMINE MALEATE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for FLUVOXAMINE MALEATE
Clinical Trial Phase	Trials
Completed	3
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for FLUVOXAMINE MALEATE

Sponsor Name

Sponsor Name for FLUVOXAMINE MALEATE
Sponsor	Trials
Solvay Pharmaceuticals	2
AbbVie	2
Meiji Seika Pharma Co., Ltd.	1

Sponsor Type

Sponsor Type for FLUVOXAMINE MALEATE
Sponsor	Trials
Industry	5
Other	5